Hangzhou Tigermed Consulting Management
Management criteria checks 4/4
Hangzhou Tigermed Consulting's CEO is Xiaochun Cao, appointed in Feb 2017, has a tenure of 7.83 years. directly owns 6% of the company’s shares, worth CN¥2.84B. The average tenure of the management team and the board of directors is 5.9 years and 3.9 years respectively.
Key information
Xiaochun Cao
Chief executive officer
CN¥1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.8yrs |
| CEO ownership | 6.0% |
| Management average tenure | 5.9yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥959m |
| Jun 30 2024 | n/a | n/a | CN¥1b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥1m | n/a | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥2b |
| Jan 01 2023 | n/a | n/a | CN¥2b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥3b |
| Jan 01 2022 | n/a | n/a | CN¥3b |
| Sep 30 2021 | n/a | n/a | CN¥2b |
| Jun 30 2021 | n/a | n/a | CN¥2b |
| Mar 31 2021 | n/a | n/a | CN¥2b |
| Dec 31 2020 | CN¥836k | n/a | CN¥2b |
| Sep 30 2020 | n/a | n/a | CN¥2b |
| Jun 30 2020 | n/a | n/a | CN¥1b |
| Mar 31 2020 | n/a | n/a | CN¥951m |
| Dec 31 2019 | CN¥784k | n/a | CN¥842m |
Compensation vs Market: Xiaochun's total compensation ($USD158.55K) is below average for companies of similar size in the CN market ($USD259.49K).
Compensation vs Earnings: Xiaochun's compensation has been consistent with company performance over the past year.
CEO
Xiaochun Cao (55 yo)
7.8yrs
Tenure
CN¥1,157,300
Compensation
Dr. Xiaochun Cao, M.D., serves as Consultant at TigerYeah Capital. She co-founded Hangzhou Tigermed Consulting Co., Ltd. and served as its Chief Financial Officer since September 17, 2021 until October 21,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 7.5yrs | CN¥2.92m | 20.58% CN¥ 9.8b | |
| Co-Founder | 7.8yrs | CN¥1.16m | 6% CN¥ 2.8b | |
| President & Executive Director | no data | CN¥2.61m | no data | |
| Chief Financial Officer | 2.2yrs | CN¥1.42m | no data | |
| Executive VP | no data | CN¥1.20m | no data | |
| Secretary | no data | CN¥656.80k | 0.0017% CN¥ 810.5k | |
| Chief Investment Officer | no data | no data | no data | |
| Head of Accounting Department | no data | no data | no data | |
| Senior VP & Chief Scientific Officer | no data | no data | no data | |
| Chief Compliance Officer | no data | no data | no data | |
| VP & Head of Data Resources Department | 5.9yrs | no data | no data | |
| Senior VP & Chief Quality Officer | no data | no data | no data |
5.9yrs
Average Tenure
53yo
Average Age
Experienced Management: 300347's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 7.5yrs | CN¥2.92m | 20.58% CN¥ 9.8b | |
| Co-Founder | 7.5yrs | CN¥1.16m | 6% CN¥ 2.8b | |
| President & Executive Director | 3.2yrs | CN¥2.61m | no data | |
| Executive VP | 1.6yrs | CN¥1.20m | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Chairman of Supervisory Committee | 4.7yrs | CN¥72.00k | no data | |
| Independent Non Executive Director | 1.6yrs | CN¥122.00k | no data | |
| Shareholder Supervisor | 4.7yrs | CN¥32.00k | no data | |
| Independent Non-Executive Director | 4.7yrs | CN¥220.00k | no data | |
| Employee Representative Supervisor | 2.3yrs | no data | no data |
3.9yrs
Average Tenure
55yo
Average Age
Experienced Board: 300347's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:21 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hangzhou Tigermed Consulting Co., Ltd is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Luo | BOCI Research Ltd. |
| Linda Lu | BOCI Research Ltd. |
| Bo Li | BofA Global Research |